m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0074)
| Name |
Beta-Elemen
|
||||
|---|---|---|---|---|---|
| Synonyms |
Beta-Elemen; (-)-beta-Elemene; Levo-beta-elemene; b-elemene; Levo-b-elemene; UNII-2QG8CX6LXD; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; (-)-b-Elemene; CHEBI:62855; 2QG8CX6LXD; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; 33880-83-0; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; beta-Elemene, (-)-; b-Elemen; E- .beta.-Elemene; Epitope ID:153551; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; DTXSID60881211; SDP-111; 8064AH; s6957; ZINC14096289; AKOS028108977; (-)-beta-Elemene, analytical standard; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, [1S-(1alpha,2beta,4beta)]-; AS-82909; HY-107324; CS-0028143; C17094; E79113; 880E830; Q27132237; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-
Click to Show/Hide
|
||||
| Status | Phase 3 | [1] | |||
| Structure |
 |
||||
| Formula |
C15H24
|
||||
| InChI |
InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1
|
||||
| InChIKey |
OPFTUNCRGUEPRZ-QLFBSQMISA-N
|
||||
| PubChem CID | |||||
Full List of m6A Targets Related to This Drug
Autophagy protein 5 (ATG5)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as Autophagy protein 5 (ATG5), ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and LC3B-II. beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
| Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | Autophagy | hsa04140 | ||
| Cell Process | Autophagic lysosome acidification | |||
| In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
| Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
| HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
| PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
| In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B/LC3B-II). beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
| Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | Autophagy | hsa04140 | ||
| Cell Process | Autophagic lysosome acidification | |||
| In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
| Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
| HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
| PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
| In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Sequestosome-1 (SQSTM1)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, ATG7, LC3B, and Sequestosome-1 (SQSTM1). beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and LC3B-II. beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
| Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | Autophagy | hsa04140 | ||
| Cell Process | Autophagic lysosome acidification | |||
| In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
| Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
| HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
| PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
| In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 could positively regulate the autophagy by targeting the autophagy-related genes such as ATG5, Ubiquitin-like modifier-activating enzyme ATG7 (ATG7), LC3B, and SQSTM1. beta-elemene inhibited the autophagy flux by preventing autophagic lysosome acidification, resulting in increasing expression of SQSTM1 and LC3B-II. beta-elemene could reverse gefitinib resistance in non-small cell lung cancer cells by inhibiting cell autophagy process in a manner of chloroquine. METTL3-mediated autophagy in reversing gefitinib resistance of NSCLC cells by beta-elemene, which shed light on providing potential molecular-therapy target and clinical-treatment method in NSCLC patients with gefitinib resistance. | |||
| Responsed Disease | Non-small-cell lung carcinoma | ICD-11: 2C25.Y | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | Autophagy | hsa04140 | ||
| Cell Process | Autophagic lysosome acidification | |||
| In-vitro Model | Gefitinib-resistant cell line HCC827GR (Gefitinib-resistant HCC827 cell line) | |||
| Gefitinib-resistant cell line PC9GR (Gefitinib-resistant PC9 cell line) | ||||
| HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
| PC-9 | Lung adenocarcinoma | Homo sapiens | CVCL_B260 | |
| In-vivo Model | NSCLC gefitinib-resistant cells (5 × 106 cells in 100 uL PBS) were injected subcutaneously into the lateral surface of the left abdomen of 6-week-old female BALB/c nude mice (at least five mice per group to ensure accuracy). | |||
References